Evusheld: UK Urged To Use RWD To Give Clinically Vulnerable Early Access To COVID-19 Treatment

Instead of waiting for AstraZeneca’s COVID-19 drug Evusheld to undergo the standard cost appraisal process, the UK government is being urged to consider alternative mechanisms to supplement its evidence base. These include setting up real-time observational studies while prioritizing the drug’s rollout in individuals deemed clinically extremely vulnerable.

The plea comes from the independent Drug Safety Research Unit (DSRU) in response to the government’s decision not to purchase any doses of the licensed drug citing “insufficient data on the duration of protection offered by Evusheld in relation to the Omicron variant